- Home
- OCSL vs PCRX Comparison
OCSL vs PCRX Comparison
Compare OCSL & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OCSL
- PCRX
- Stock Information
- Founded
- OCSL 2007
- PCRX 2006
- Country
- OCSL United States
- PCRX United States
- Employees
- OCSL N/A
- PCRX N/A
- Industry
- OCSL Finance: Consumer Services
- PCRX Biotechnology: Pharmaceutical Preparations
- Sector
- OCSL Finance
- PCRX Health Care
- Exchange
- OCSL Nasdaq
- PCRX Nasdaq
- Market Cap
- OCSL 1.3B
- PCRX 1.2B
- IPO Year
- OCSL 2008
- PCRX 2011
- Fundamental
- Price
- OCSL $16.03
- PCRX $25.16
- Analyst Decision
- OCSL Hold
- PCRX Buy
- Analyst Count
- OCSL 7
- PCRX 9
- Target Price
- OCSL $16.75
- PCRX $26.22
- AVG Volume (30 Days)
- OCSL 670.7K
- PCRX 805.4K
- Earning Date
- OCSL 02-04-2025
- PCRX 02-27-2025
- Dividend Yield
- OCSL 11.73%
- PCRX N/A
- EPS Growth
- OCSL N/A
- PCRX N/A
- EPS
- OCSL 0.67
- PCRX N/A
- Revenue
- OCSL $370,327,000.00
- PCRX $694,957,000.00
- Revenue This Year
- OCSL N/A
- PCRX $5.55
- Revenue Next Year
- OCSL N/A
- PCRX $5.64
- P/E Ratio
- OCSL $23.93
- PCRX N/A
- Revenue Growth
- OCSL N/A
- PCRX 4.40
- 52 Week Low
- OCSL $14.89
- PCRX $11.16
- 52 Week High
- OCSL $20.43
- PCRX $31.67
- Technical
- Relative Strength Index (RSI)
- OCSL 59.53
- PCRX 52.48
- Support Level
- OCSL $15.33
- PCRX $25.41
- Resistance Level
- OCSL $15.88
- PCRX $26.89
- Average True Range (ATR)
- OCSL 0.23
- PCRX 1.18
- MACD
- OCSL 0.04
- PCRX -0.36
- Stochastic Oscillator
- OCSL 88.78
- PCRX 4.35
About OCSL Oaktree Specialty Lending Corporation
Oaktree Specialty Lending Corp is a specialty finance company. The company provides lending services and invests in small and mid-sized companies. The company's investment objective is to maximize its portfolio's total return by generating current income from debt investments, and to a lesser extent, capital appreciation from equity investments. The company provides customized, one-stop credit solutions to companies with limited access to public or syndicated capital markets.
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company has three commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.